Mark Goodman

Salix Pharmaceutical's (NASDAQ: SLXP) $2.7 billion inversion deal disappointed investors Wednesday who complain it dilutes near-term earnings and makes Salix seem like an unlikely merger candidate any time soon. Salix said after the bell Tuesday it will acquire the Irish unit of Italy's...